STAT+: For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune
Last month, word spread that a drug was finally shown to slow Alzheimer’s disease, and…
Category: STAT+
STAT+: As small-town telepharmacies struggle to stay open, national chains eye an opportunity
In February 2019, the town of Albion, Ind. — population 2,500 — welcomed its first…
STAT+: European Commission says preliminary findings indicate Teva violated antitrust rules
After three years of probing, the European Commission has reached a preliminary decision that Teva…
STAT+: Merck touts positive results on key drug from $11.5 billion Acceleron merger
Merck said Monday the key drug from its $11.5 billion purchase of the biotech Acceleron…
STAT+: Second U.S. oncology provider plans to go public
The U.S. is about to have not just one, but two, standalone publicly-traded oncology providers….
STAT+: Merck’s Covid-19 pill was no better than placebo in lowering the risk of hospitalization
A Merck pill used to combat Covid-19 failed to demonstrate it can lower the risk…
STAT+: Medicare Advantage quality ratings plunge as government resets to pre-pandemic standards
Federal officials significantly reduced the quality scores of next year’s Medicare Advantage plans, a move…
STAT+: Biogen CEO search focuses on scientists, with former J&J exec as a leading candidate
A senior researcher who was most recently at Johnson & Johnson has emerged as a…
STAT+: Pharmalittle: Medicare can still penalize drugmakers for hiking prices to privately insured patients; FDA explains push to withdraw premature-birth drug
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Health plans say texting could help reach underserved patients. But a federal rule is getting in their way
Health plans trying to reach low-income and underserved customers say they’re being stymied by a…
STAT+: Drugmakers will be penalized if they hike prices on patients in private insurance market
WASHINGTON — Democrats’ drug pricing law will still penalize drugmakers if they hike prices on…
STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty
Rise and shine, everyone, another busy day is on the way. And this is especially…
STAT+: ‘Patchy efforts’ by major insulin makers mean access lags in many poor countries
The three companies that dominate the global market for insulin have launched various programs to…
STAT+: Medicare tasks a senior adviser with staffing its new drug pricing division
WASHINGTON — Medicare has tasked a senior adviser at the agency with assembling a small…
STAT+: Alzheimer’s clinical trials have a recruitment problem. Telehealth platform Ro thinks it can help
Telehealth company Ro has reached an agreement with the National Institute on Aging to create…
STAT+: Errors have plagued insurance directories of doctors. The government wants to clean them up with its own
The federal government wants to create a national directory that houses accurate, up-to-date information for…
STAT+: Pharmalittle: Nobel awarded for novel chemistry used in drug development; Biden will nominate surgeon general for WHO post
Good morning, Pharmalitte students. I’m Allison DeAngelis, substituting for Ed today. It’s a rainy day…
STAT+: The Q4 health tech tracker: 17 key industry events and milestones to watch
Health tech companies and their backers are increasingly cautious as they brace for uncertain market…
.jpg)
STAT+: Pharmalittle: U.S. Supreme Court asks solicitor general for views on ‘skinny label’ case; Express Scripts and Kroger are mired in dispute
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: CAR-T therapy doesn’t work in all cancer cases. Scientists are starting to figure out why
When CAR-T therapy works against blood cancer, it can work spectacularly, but cancer still returns…
STAT+: At Verily, a growing line of business builds on a revolving door to the FDA
After years spent building a seemingly slapdash set of medical initiatives, Verily seems to have…
STAT+: Pharmalittle: Price of new ALS drug prompts criticism; many drug price hikes exceeded U.S. inflation rate
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Many trials to confirm benefits of drugs granted accelerated approvals are running late
Amid heightened debate over a regulatory program for speeding the approval of some medicines, a…
STAT+: Epic overhauls popular sepsis algorithm criticized for faulty alarms
Epic Systems has revamped its widely criticized sepsis prediction model in a bid to improve…
.jpg)
STAT+: Pharmalittle: FDA approves a medicine to combat ALS; Medicare drug-price talks are poised to become a legal battle
And so, another working week will soon draw to a close. Not a moment too…
STAT+: The biotech scorecard for the fourth quarter: 13 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth…
FDA approves ALS drug from Amylyx, giving patients a much-needed treatment option
The Food and Drug Administration approved a new medicine for ALS from Amylyx Pharmaceuticals on…
STAT+: Health app companies wrestle with how to design studies to prove treatments work
For companies that have spent years developing interactive technologies to help treat disease, the tricky…
STAT+: With rivals on its heels, Illumina launches a new line of high-end DNA sequencers
SAN DIEGO — After a steep drop in its stock price and with mounting competition…
STAT+: Pharmalittle: Medicare plans sizable infrastructure for negotiating drug prices; Alzheimer’s data also boost Roche and Lilly
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Medicare lays out the bureaucracy it will need to negotiate drug prices
WASHINGTON — New documents obtained by STAT outline how Medicare is planning to build out…
STAT+: Burning questions left unanswered about the latest Alzheimer’s therapy
News of the first clearly successful clinical trial for a new Alzheimer’s disease treatment in…
STAT+: A ‘disaster’, or a ‘clear path’ forward?: New FDA guidance on AI in medicine sparks strong reactions
New guidance from the Food and Drug Administration is triggering strong reaction from researchers and…
STAT+: If a new Alzheimer’s drug works, was there any point to the Aduhelm controversy? Yes
The announcement Tuesday night from Eisai and Biogen that their experimental medicine, lecanemab, reduced Alzheimer’s…
STAT+: Pharmalittle: Biogen Alzheimer’s drug slowed cognitive decline in a trial; European pharma warns energy costs may halt some generic production
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Lilly is accused by the federal government of discriminating against older sales reps
In an unusual move, the U.S. Equal Employment Opportunity Commission has filed a lawsuit accusing…
Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
An investigational Alzheimer’s disease treatment from Biogen and Eisai slowed the rate of cognitive decline…
STAT+: Top FDA official acknowledges agency’s slow process for reviewing health app updates
The Food and Drug Administration’s approach to reviewing updates to software products is far slower…
STAT+: Pharmalittle: Democrats concede on passing ‘clean’ FDA funding bill; Biogen whistleblower nets $250 million
Good morning, one and all. Damian here, filling in for Ed Silverman once more. Here…
STAT+: Google and Fitbit launch new cloud tools to help hospitals use wearables
Google Cloud and Fitbit are rolling out a new offering they hope will ease some…
STAT+: Democrats concede to clean user fee agreement to fund FDA
WASHINGTON — Democrats have conceded to Republican demands and agreed to fund the Food and…
STAT+: Pharmalittle: GSK picks its first female CFO; Pfizer advances Omicron booster for kids
Good morning, everyone. Damian Garde here, filling in for Ed Silverman at the outset of…
STAT+: Health insurers are painting a misleading picture of Medicare Advantage savings, experts say
The health insurance industry is continuing its campaign to convince the public that Medicare Advantage…
STAT+: Biotech turns to new and strange viruses to overcome gene therapy’s limitations
CAMBRIDGE, Mass. — The fluorescent orange sticker atop the white machine reads “BIOHAZARD,” but it’s a…
STAT+: Some European regulators are starting to take steps to ensure clinical trial results are reported
Regulators in half a dozen European countries are now taking steps to enforce requirements that…
STAT+: Zuckerberg, Chan want new Harvard institute to answer questions about the brain and AI
For the first time since gifting Harvard University $500 million to launch a new research institute,…
STAT+: Pharmalittle: U.S. drug net prices fell nearly 8% in the second quarter; FDA panel favors fecal-based therapy for bacterial infections
And so, another working week will soon draw to a close. Not a moment too…
STAT+: White House pitches drug pricing reforms as a way to extend cancer patients’ lives
WASHINGTON — The White House is pitching an added benefit to Democrats’ recent drug pricing…
STAT+: Inflation caused another big drop in net drug prices, analysis finds
Amid ongoing debate over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: New details on Apple Watch study emphasize Medicaid enrollment
Newly published details about a high-profile Apple Watch study calls it “a priority” to recruit…